APP Arctic Mutation (APP Arctic)

APP Arctic Mutation (APP Arctic)

The APP Arctic mutation (E693G) is a pathogenic mutation in the [amyloid precursor protein](/proteins/app-protein) gene that causes familial [Alzheimer's disease](/diseases/alzheimers-disease). Unlike other APP mutations that increase [Aβ](/proteins/amyloid-beta) production, the Arctic mutation enhances Aβ aggregation and protofibril formation. This mutation was instrumental in shifting research focus toward Aβ oligomers as the true toxic species in AD. [@reactive]

Overview

The APP Arctic mutation (E693G) is a pathogenic mutation in the [amyloid precursor protein](/proteins/app-protein) gene that causes familial Alzheimer's disease. Unlike other APP mutations that increase Aβ production, the Arctic mutation enhances Aβ aggregation and protofibril formation. This mutation was instrumental in shifting research focus toward Aβ oligomers as the true toxic species in AD. [@reactive]

Genetic Background

• Gene: APP (Amyloid Precursor Protein)
• Chromosome: 21q21.3
• Mutation: E693G (Glu693Gly)
• cDNA Change: c.2128A>G
• Discovery: 1998, Swedish family (Nordstedt et al.)
• Inheritance: Autosomal dominant

Mechanism

Effect on APP Processing

• Location: Within the Aβ sequence (Aβ position 22)
• Effect: Does NOT significantly increase total Aβ production
• Primary effect: Alters Aβ aggregation properties

Aβ Alterations

...

APP Arctic Mutation (APP Arctic)

The APP Arctic mutation (E693G) is a pathogenic mutation in the [amyloid precursor protein](/proteins/app-protein) gene that causes familial [Alzheimer's disease](/diseases/alzheimers-disease). Unlike other APP mutations that increase [Aβ](/proteins/amyloid-beta) production, the Arctic mutation enhances Aβ aggregation and protofibril formation. This mutation was instrumental in shifting research focus toward Aβ oligomers as the true toxic species in AD. [@reactive]

Overview

The APP Arctic mutation (E693G) is a pathogenic mutation in the [amyloid precursor protein](/proteins/app-protein) gene that causes familial Alzheimer's disease. Unlike other APP mutations that increase Aβ production, the Arctic mutation enhances Aβ aggregation and protofibril formation. This mutation was instrumental in shifting research focus toward Aβ oligomers as the true toxic species in AD. [@reactive]

Genetic Background

• Gene: APP (Amyloid Precursor Protein)
• Chromosome: 21q21.3
• Mutation: E693G (Glu693Gly)
• cDNA Change: c.2128A>G
• Discovery: 1998, Swedish family (Nordstedt et al.)
• Inheritance: Autosomal dominant

Mechanism

Effect on APP Processing

• Location: Within the Aβ sequence (Aβ position 22)
• Effect: Does NOT significantly increase total Aβ production
• Primary effect: Alters Aβ aggregation properties

Aβ Alterations

• Production: Normal or slightly reduced
• Aggregation: Markedly accelerated
• Protofibrils: Increased formation of toxic Aβ protofibrils
• Oligomerization: Enhanced soluble oligomer formation

The Arctic mutation demonstrates that:

• Toxicity is not just about Aβ quantity
• Aβ aggregation kinetics are critical to pathogenesis
• Protofibrils and oligomers may be more toxic than plaques

Clinical Significance

Age of Onset

• Typical onset: 55-70 years
• Similar to sporadic AD in timing

Phenotype

• Cognitive decline: Typical AD presentation
• Memory loss: Prominent early feature
• Progression: Similar rate to typical AD

Neuropathology

• Plaques: Fewer dense-core plaques than other APP mutations
• Oligomers: High burden of soluble Aβ oligomers
• Vascular amyloid: Less severe than Flemish/Dutch mutations

Research Significance

Implications for Therapy

Anti-aggregation drugs: The Arctic mutation validates aggregation inhibitors

Oligomer-targeting therapies: Antibodies against oligomers may be effective

BACE inhibitors: May be less effective (production not increased)

Animal Models

• APP Arctic mice: Show cognitive deficits with minimal plaque deposition
• Demonstrate: Oligomer toxicity independent of plaque burden

Recent Research (2024-2026)

• [Oral administration of arginine suppresses Aβ pathology in animal models of Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/41175945/) (2025 Dec) - Neurochemistry International
• [Somatostatin therapy, neprilysin activation, and amyloid beta reduction: A novel approach for Alzheimer's treatment](https://pubmed.ncbi.nlm.nih.gov/40633205/) (2025 Aug) - Biomedicine & Pharmacotherapy
• [Reactive Astrocytes with Reduced Function of Glutamate Transporters in the App(NL-G-F) Knock-in Mice](https://pubmed.ncbi.nlm.nih.gov/40421586/) (2025 Jun) - ACS Chemical Neuroscience
• [Distinct Chemical Determinants are Essential for Achieving Ligands for Superior Optical Detection of Specific Amyloid-β Deposits in Alzheimer's Disease](https://pubmed.ncbi.nlm.nih.gov/39508558/) (2024 Dec) - ChemistryOpen
• [Impairments in Spatial Representations of Place Cells and Neural rhythms in APP knock-in rat model](https://pubmed.ncbi.nlm.nih.gov/40031499/) (2024 Jul) - IEEE EMBC

See Also

• [APP Gene](/genes/app)
• [Amyloid-Beta Protein](/proteins/amyloid-beta)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [APP Swedish Mutation](/diseases/app-swedish-mutation)
• [APP Flemish Mutation](/diseases/app-flemish-mutation)

Structural Biology

Cryo-EM Findings

Recent cryo-EM structural studies (2023) have resolved amyloid-beta filament structures from patients with the Arctic mutation, revealing distinct conformational differences from other Aβ aggregates. These structural insights explain the mutation's unique pathogenicity and may guide the development of aggregation inhibitors targeting protofibril formation.

Aβ Filament Differences

• Arctic mutation causes distinct Aβ filament conformations
• The E22G substitution (within Aβ sequence) alters protofibril stability
• Filaments show enhanced resistance to proteolytic clearance

Therapeutic Implications

The mutation's location within the Aβ peptide itself makes it a valuable model for testing therapies targeting protofibril formation and aggregation. Key therapeutic approaches include:

Aggregation Inhibitors

• Small molecules targeting Aβ protofibril stabilization
• Antibodies recognizing oligomeric Aβ species
• Peptide-based inhibitors of Aβ aggregation

Neprilysin Enhancement

• Somatostatin therapy upregulates neprilysin (PMID: 40633205(https://pubmed.ncbi.nlm.nih.gov/40633205/))
• Enhanced Aβ clearance through endogenous degradation pathways

Translational Research

• APP knock-in models carrying this mutation show SDS-insoluble Aβ deposits
• Mimics human AD brain pathology - useful for testing amyloid-targeting drugs
• Enables evaluation of therapies targeting oligomerization kinetics

External Links

• [APP Arctic Mutation - MedGen (NIH)](https://medgen.nlm.nih.gov/220361)
• [Alzheimer's Disease Mutations Database - APP](https://alzgene.org/APP)
• [OMIM: 604334 - APP](https://www.omim.org/entry/604334)
• [ClinVar: APP Arctic](https://www.ncbi.nlm.nih.gov/clinvar/variation/41364)
• [Alzheimer's Association](https://www.alz.org/)
• [NIH National Institute on Aging - Alzheimer's Disease](https://www.nia.nih.gov/health/alzheimers)

References

[Unknown, Oral administration of arginine suppresses Aβ pathology in animal models of Alzheimer's disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41175945/)

[Unknown, Somatostatin therapy, neprilysin activation, and amyloid beta reduction: A novel approach for Alzheimer's treatment (n.d.)](https://pubmed.ncbi.nlm.nih.gov/40633205/)

[Unknown, Reactive Astrocytes with Reduced Function of Glutamate Transporters in the App(NL-G-F) Knock-in Mice (n.d.)](https://pubmed.ncbi.nlm.nih.gov/40421586/)

[Unknown, Distinct Chemical Determinants are Essential for Achieving Ligands for Superior Optical Detection of Specific Amyloid-β Deposits in Alzheimer's Disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/39508558/)

[Unknown, Impairments in Spatial Representations of Place Cells and Neural rhythms In APP knock-in rat model (n.d.)](https://pubmed.ncbi.nlm.nih.gov/40031499/)